Adagio Therapeutics, Inc. ADGI
4.64 0.00 (+0.00%)
At closeSep 13, 2022, 12:00 AM EDT
4.40 Day range 4.74
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 3.83 -17.5% downside
Now 4.64
- Target (low)
- 3.00
- Target (mean)
- 3.83
- Target (high)
- 5.00
Ratings (-1m) 4 0 buy · 3 hold · 1 sell
- Strong buy0
- Buy0
- Hold3
- Sell1
- Strong sell0
Recommendation trend
- 1 month ago 4
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.49 | -0.52 – -0.46 | -0.98 | +50.0% | 0 | 0.0% | 3 |
| Next quarter | -0.52 | -0.60 – -0.39 | -0.77 | +32.5% | 0 | 0.0% | 3 |
| Current year | -2.40 | -2.48 – -2.25 | -5.32 | +54.9% | 0 | 0.0% | 3 |
| Next year | -1.98 | -2.38 – -1.31 | -2.40 | +17.5% | 10.23M | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 2022 | Morgan Stanley | Maintained | — | Underweight |
| May 17, 2022 | Morgan Stanley | Maintained | — | Underweight |
| Jan 6, 2022 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| Dec 22, 2021 | Jefferies | Downgrade | Buy | Hold |
| Dec 15, 2021 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Dec 15, 2021 | Guggenheim | Downgrade | Buy | Neutral |
| Dec 15, 2021 | Stifel | Downgrade | Buy | Hold |
| Nov 29, 2021 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Aug 31, 2021 | Morgan Stanley | Initiated | — | Equal-Weight |
| Aug 31, 2021 | Jefferies | Initiated | — | Buy |
| Aug 31, 2021 | Stifel | Initiated | — | Buy |
| Aug 31, 2021 | Guggenheim | Initiated | — | Buy |